Ascletis Completes Enrollment for Exciting Acne Treatment Trial

Ascletis Completes Enrollment for Phase III Trial of ASC40

Ascletis Pharma Inc. has successfully enrolled a total of 480 patients for the Phase III clinical trial of ASC40, also known as denifanstat. This once-daily oral tablet aims to treat moderate to severe acne, a condition that affects countless individuals worldwide. The enrollment was completed recently, and anticipation is building as topline results are expected in the second quarter of 2025.

Details of the Phase III Trial

This comprehensive Phase III trial involves a randomized, double-blind, placebo-controlled design and is being conducted across multiple centers. The primary goal is to assess the safety and efficacy of ASC40 in managing symptoms associated with acne vulgaris. Patients will be divided into two groups: one group will receive a 50 mg dose of ASC40 daily, while the other group will receive a matching placebo for a duration of 12 weeks. This setup ensures that the results will be robust and reliable.

What the Trial Aims to Achieve

Key efficacy metrics will focus on the proportion of patients who achieve treatment success by week 12. Treatment success is defined as a minimum of a 2-point reduction in the Investigator's Global Assessment (IGA) score, along with achieving a score of clear (0) or almost clear (1). Other endpoints will include assessing the change in total lesion count and inflammatory lesion count from baseline at week 12.

Promising Phase II Results

Before this Phase III trial, Ascletis reported favorable results from the Phase II trial for ASC40. This trial demonstrated that 19.4% of participants met the treatment success criteria by week 12, significantly outperforming the placebo group, which had a mere 5.1% success rate.

Understanding ASC40's Mechanism

ASC40 is groundbreaking as a first-in-class medication. Its selective mechanism involves inhibiting fatty acid synthase (FASN) and directly reducing sebum production by targeting de novo lipogenesis within sebocytes. In addition, it helps to manage inflammation by decreasing cytokine secretion and inhibiting Th17 differentiation. This dual approach addresses both the causes and symptoms of acne effectively.

Comment from Ascletis Leadership

Dr. Jinzi J. Wu, the Founder, Chairman, and CEO of Ascletis, expressed optimism about the trial’s progress. He stated, "As a first-in-class once-daily oral drug candidate with a novel mechanism for acne treatment, ASC40 has shown positive efficacy and a good safety profile in the Phase II study. We look forward to announcing topline results of the ASC40 (denifanstat) Phase III trial in the second quarter of 2025." This illustrates the company's commitment to developing effective treatments that address unmet medical needs.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a biotech firm listed on the Hong Kong Stock Exchange. The company is dedicated to groundbreaking research and development, covering a comprehensive range from drug discovery to GMP manufacturing. With a skilled management team that has a proven track record, Ascletis is focused on developing innovative treatments for critical areas such as metabolic and viral diseases.

Contact Information

For further inquiries, you can reach out to Peter Vozzo at ICR Healthcare at 443-231-0505. Ascletis Pharma Inc. is also available at +86-181-0650-9129 for inquiries related to their ongoing clinical trials and updates.

Frequently Asked Questions

What is the ASC40 trial about?

The ASC40 trial is a Phase III study evaluating the safety and efficacy of a once-daily oral tablet for the treatment of moderate to severe acne.

How many patients are enrolled in the trial?

A total of 480 patients have been enrolled in the Phase III trial for ASC40.

When can we expect results from the trial?

Topline results from the trial are anticipated in the second quarter of 2025.

What were the outcomes of the Phase II trial?

The Phase II trial showed that 19.4% of patients achieved treatment success, surpassing the placebo group's 5.1% success rate.

Who is leading Ascletis Pharma Inc.?

Dr. Jinzi J. Wu is the Founder, Chairman, and CEO of Ascletis Pharma Inc.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.